Sandip Samaddar1, Somnath Das2, Sumit Gupta3
Glaucoma affects more than 67 million persons worldwide of whom about 10% or million are estimated to be blind. In India
12.8% of blindness are reported to occur due to glaucoma. Trabeculectomy is the standard surgical procedure for the reduction
of Intraocular Pressure (IOP) in glaucoma patients. But, introduction of adjunctive antimetabolites like Mitomycin C (MMC) and
O logen , a biodegradable, porous, porcine, collagen implant significantly decrease the postoperative subconjunctival scarring
with formation of an ideal bleb leading to improved long term success of trabeculectomy.
aim of the study is to compare the outc omes of trabeculectomy with or without O logen implant and adjunctive
antimetabolites in patients requiring glaucoma surgery for uncontrolled intraocular pressure.
MATERIALS AND METHODS
prospective randomi s ed comparative study was conducted in the glaucoma clinic at the Regional Institute of Ophthalmology
(RIO), Medical College and Hospital, Kolkata during a period of 12 months (January 2015 January 2016). 60 glaucomatous
eyes (either POAG or PACG) of patients who are attending glaucoma clinic of RIO during the study period and were fit for
filtration surgery were selected by simple random selection.
MMC and Ologen implant have better success rate over simple trabeculectomy in terms of IOP control.
There was no statistically
significant difference between the three groups regarding age. The absolute success rate at 6th month postoperatively were
60% in group 1 and 80% in group 2 and group 3 showing no significant difference between group 2 and group 3. But the
success rate was significan tly lower in trabeculectomy group than that of other two groups.
Ologen implant in trabeculectomy could be a new, safe and effective alternative treatment to MMC with similar success rate on
6 months follow up. This implant may for instance be preferred when antimetabolite related risks need to be avoided.